Unii-jwf2N75yqj | 571141-49-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: Unii-jwf2N75yqj
• 英文别名: (2R,3R,4S)-6-amino-4-[4-chloro-N-(1H-imidazol-2-ylmethyl)anilino]-2-(dimethoxymethyl)-2-methyl-3,4-dihydrochromen-3-ol
• CAS: 571141-49-6
• 化学式: C₂₃H₂₇ClN₄O₄
• 分子量: 458.9
• InChiKey: XPQNJJQQAZIHMI-QZNHQXDQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  32
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  106
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  (2R,3R,4S)-6-nitro-4-[N-(4-chlorophenyl)-N-(1H-imidazol-2-ylmethyl)amino]-3-hydroxy-2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran 在 钯 氢气 、 silica gel 、 甲醇 、 二氯甲烷 作用下， 以 甲醇 为溶剂， 25.0 ℃ 、40.53 MPa 条件下， 反应 12.0h， 以to afford the title compound (368 mg, 75%)的产率得到Unii-jwf2N75yqj
  参考文献：
  名称：

  Benzopyran derivatives substituted with secondary amines including imidazole, their preparation and pharmaceutical compositions containing them

  摘要：

  本发明涉及用次生胺包括咪唑基取代的苯并吡喃衍生物，以及它们的制备和含有它们的药物组合物。本发明在药理学上对治疗癌症、类风湿性关节炎和糖尿病视网膜病具有抗血管生成作用，同时在保护心脏和神经细胞免受缺血再灌注损伤或保护器官方面在药理学上也有用处。

  公开号：

  US07279497B2

文献信息

• PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MACULAR DEGENERATION
  申请人：Yi Kyu-Yang

  公开号：US20140018402A1

  公开（公告）日：2014-01-16

  The present invention provides a pharmaceutical composition for preventing or treating macular degeneration, which comprises benzopyran derivatives substituted with secondary amines including imidazole or pharmaceutically acceptable salts thereof as an active ingredient. The pharmaceutical composition of the present invention may be used in the form of eye drops.

  本发明提供了一种用于预防或治疗黄斑退化的药物组合物，其包括以含有咪唑等次生胺的苯并吡喃衍生物或其药学上可接受的盐为活性成分。本发明的药物组合物可以以眼药水的形式使用。
• METHOD FOR PURIFYING BENZOPYRAN DERIVATIVE, CRYSTAL FORM THEREOF, AND METHOD FOR PREPARING CRYSTAL FORM
  申请人：Hanlim Pharmaceutical Co., Ltd.

  公开号：EP3381914A1

  公开（公告）日：2018-10-03

  The present invention provides a process for purifying (2R,3R,4S)-6-amino-4-[N-(4-chlorophenyl)-N-(1H-imidazol-2-ylmethyl)amino]-3-hydroxy -2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran, comprising converting an amorphous (2R,3R,4S)-6-amino-4-[N-(4-chlorophenyl)-N-(1H-imidazol-2-ylmethyl)amino]-3-hydroxy -2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran to a crystalline form thereof. And also, the present invention provides a novel crystalline form of (2R,3R,4S)-6-amino-4-[N-(4-chlorophenyl)-N-(1H-imidazol-2-ylmethyl)amino]-3-hydroxy -2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran and processes for preparing the same.

  本发明提供了一种纯化(2R,3R,4S)-6-氨基-4-[N-(4-氯苯基)-N-(1H-咪唑-2-基甲基)氨基]-3-羟基-2-甲基-2-二甲氧基甲基-3,4-二氢-2H-1-苯并吡喃的工艺、包括将无定形的(2R,3R,4S)-6-氨基-4-[N-(4-氯苯基)-N-(1H-咪唑-2-基甲基)氨基]-3-羟基-2-甲基-2-二甲氧基甲基-3,4-二氢-2H-1-苯并吡喃转化为其结晶形式。此外，本发明还提供了(2R,3R,4S)-6-氨基-4-[N-(4-氯苯基)-N-(1H-咪唑-2-基甲基)氨基]-3-羟基-2-甲基-2-二甲氧基甲基-3,4-二氢-2H-1-苯并吡喃的新型结晶形式及其制备工艺。
• EYE DROPS IN FORM OF SOLUTION COMPRISING BENZOPYRAN DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
  申请人：Hanlim Pharmaceutical Co., Ltd.

  公开号：EP3760188A1

  公开（公告）日：2021-01-06

  The present invention provides an eye drop formulation in the form of a solution, comprising (2R,3R,4S)-6-amino-4-[N-(4-chlorophenyl)-N-(1H-imidazol-2-ylmethyl)amino]-3-hydroxy -2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran or a pharmaceutically acceptable salt thereof; propylene glycol as a stabilizing agent; and a pH controlling agent in an aqueous medium, wherein the eye drop formulation has a pH ranging from 4.0 to 5.0. The eye drop formulation of the present invention can contain (2R,3R,4S)-6-amino-4-[N-(4-chlorophenyl)-N-(1H-imidazol-2-ylmethyl)amino]-3-hydroxy -2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran or a pharmaceutically acceptable salt thereof in a high concentration; and has an excellent stability. In addition, the pharmaceutical product for preventing or treating macular degeneration according to the present invention can be stored for extended periods.

  本发明提供了一种溶液形式的滴眼剂配方，包含(2R,3R,4S)-6-氨基-4-[N-(4-氯苯基)-N-(1H-咪唑-2-基甲基)氨基]-3-羟基-2-甲基-2-二甲氧基甲基-3,4-二氢-2H-1-苯并吡喃或其药学上可接受的盐；丙二醇作为稳定剂；以及水介质中的 pH 值控制剂，其中滴眼剂配方的 pH 值范围为 4.0至5.0。本发明的滴眼液制剂可含有高浓度的(2R,3R,4S)-6-氨基-4-[N-(4-氯苯基)-N-(1H-咪唑-2-基甲基)氨基]-3-羟基-2-甲基-2-二甲氧基甲基-3,4-二氢-2H-1-苯并吡喃或其药学上可接受的盐，并具有极佳的稳定性。此外，根据本发明生产的用于预防或治疗黄斑变性的药品可以长期储存。
• Pharmaceutical composition for preventing or treating macular degeneration
  申请人：KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

  公开号：US10485786B2

  公开（公告）日：2019-11-26

  The present invention provides a pharmaceutical composition for preventing or treating macular degeneration, which comprises benzopyran derivatives substituted with secondary amines including imidazole or pharmaceutically acceptable salts thereof as an active ingredient. The pharmaceutical composition of the present invention may be used in the form of eye drops.

  本发明提供了一种用于预防或治疗黄斑变性的药物组合物，其活性成分包括被包括咪唑在内的仲胺取代的苯并吡喃衍生物或其药学上可接受的盐类。本发明的药物组合物可以滴眼液的形式使用。
• Method for purifying benzopyran derivative, crystal form thereof, and method for preparing crystal form
  申请人：HANLIM PHARMACEUTICAL CO., LTD.

  公开号：US10487074B2

  公开（公告）日：2019-11-26

  The present invention provides a process for purifying (2R,3R,4S)-6-amino-4-[N-(4-chlorophenyl)-N-(1H-imidazol-2-ylmethyl)amino]-3-hydroxy-2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran, comprising converting an amorphous (2R,3R,4S)-6-amino-4-[N-(4-chlorophenyl)-N-(1H-imidazol-2-ylmethyl)amino]-3-hydroxy-2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran to a crystalline form thereof. And also, the present invention provides a novel crystalline form of (2R,3R,4S)-6-amino-4-[N-(4-chlorophenyl)-N-(1H-imidazol-2-ylmethyl)amino]-3-hydroxy-2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran and processes for preparing the same.

  本发明提供了一种纯化(2R,3R,4S)-6-氨基-4-[N-(4-氯苯基)-N-(1H-咪唑-2-基甲基)氨基]-3-羟基-2-甲基-2-二甲氧基甲基-3,4-二氢-2H-1-苯并吡喃的工艺、包括将无定形的(2R,3R,4S)-6-氨基-4-[N-(4-氯苯基)-N-(1H-咪唑-2-基甲基)氨基]-3-羟基-2-甲基-2-二甲氧基甲基-3,4-二氢-2H-1-苯并吡喃转化为其结晶形式。此外，本发明还提供了(2R,3R,4S)-6-氨基-4-[N-(4-氯苯基)-N-(1H-咪唑-2-基甲基)氨基]-3-羟基-2-甲基-2-二甲氧基甲基-3,4-二氢-2H-1-苯并吡喃的新型结晶形式及其制备工艺。